ARTICLE | Company News
Celgene sales and marketing update
July 11, 2016 7:00 AM UTC
The U.K.’s NICE issued a final appraisal determination (FAD) recommending against the use of Vidaza azacitidine from Celgene to treat patients at least 65 years of age who are not eligible for hemato...